2013-03-20 07:31:56 -
Medigene AG /
Medigene and SynCore expand partnership for marketing Veregen® in Asia,
Australia and New Zealand
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/ Munich, March 20, 2013. Medigene AG (Frankfurt, Prime Standard) and
SynCore Biotechnology Co., Ltd. ("SynCore"), a member of the Sinphar
Pharmaceutical Group, have expanded the existing exclusive licensing and supply
contract into new regions for the supply and marketing of the Veregen(®
)ointment for the treatment of genital warts. Along with existing agreements in
Taiwan, SynCore will now be responsible for the approval process and
commercialization of the drug for the treatment of genital warts throughout
Asia* (excl. China and Korea), in Australia and New Zealand. In addition to
income from the production and supply of the ointment and the active ingredient,
Medigene will receive payment when specific milestones are reached. Medigene
already has partnerships in Asia for the distribution of Veregen(®) in China (GC
Rise Pharmaceutials) and South Korea (Kolon Pharmaceuticals).
Dr. Frank Mathias, CEO of Medigene AG comments: "We are delighted that we have
intensified our partnership with SynCore further. Alongside the co-development
and commercialization partnership for our drug candidate EndoTAG(®)-1 which was
entered into last year, we have now also been able to significantly expand our
collaboration for the marketing of Veregen(®). Together with SynCore and our
other Asian distribution partners, we will be able to tap into the markets with
Veregen(®) in Asia and the key region of Oceania as quickly as possible."
Veregen(®) is already marketed in the USA (by Fougera), in Germany, Austria,
Switzerland (by Abbott) and Spain (by Bial). Market authorization has been
granted for other countries or is expected within the next few months. A number
of partnerships are in place in Europe, Asia and America for the marketing of
Veregen(®). Medigene intends to conclude further marketing partnerships in
additional countries to fully exploit the market potential of Veregen(®).
* Afghanistan, Bangladesh, Bhutan, Brunei, Burma, Cambodia, Indonesia, Iran,
Iraq, Japan, Laos, Maldives, Mongolia, Nepal, Pakistan, Philippines, Singapore,
Sri Lanka, Thailand and Vietnam.
About Veregen(®): Veregen(®), an ointment used in the topical treatment of
external genital warts, contains a catechin concentrate based on a defined
extract obtained from green tea leaves. Since 2010, Veregen® (Sinecatechins 15%
ointment) has been recommended in the US Department of Health and Human Services
Center for Disease Control and Prevention's Sexually Transmitted Diseases
Treatment Guidelines as a possible option for treating genital warts.
Sinecatechins 10% & 15% ointment (Veregen®) was recently also included in the
European Guideline for the Management of Anogenital Warts.
About SynCore: SynCore Biotechnology Co., Ltd, a joint venture between Sinphar
Pharmaceutical Co., Ltd and the National Health Research Institute Taiwan,
focuses on the development and pipeline management of new drugs. Currently,
SynCore has five products under development in different stages of clinical
trial. Additionally, SynCore has been granted the exclusive development and
marketing right in Asia for a new drug for the treatment of dry AMD (age-related
macular degeneration) from MacuCLEAR, an US-based biotech company; the drug
received approval to enter into phase II/III clinical trial in the US and
Taiwan. For further information, please visit www.syncorebio.com.
About Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock
Exchange, Symbol: 1734), with subsidiaries in China and Canada, specializes in
the sales and marketing of pharmaceutical products and dietary supplements as
well as in manufacturing for several global pharma companies like Johnson &
Johnson, Takeda, Shionogi and Astellas. Additionally, Sinphar is one of the
largest producers of paclitaxel (Phyxol(®)) in Asia. It is also involved in the
research and development of botanical new drugs. Further information can be
obtained at www.sinphar.com.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene was the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®), and is developing an
innovative vaccine technology. For more information, please visit
www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E(®
)is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Kontakt
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email:
investor@medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press Release as PDF:
hugin.info/132073/R/1686448/552802.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1686448]
